Compass Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

CMPX$0.84+10.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except par value per share data)

	December 31,
	2025	2024
Assets
Current assets:
Cash and cash equivalents	$30,643	$43,483
Marketable securities	178,263	83,239
Prepaid expenses and other current assets	913	6,029
Total current assets	209,819	132,751
Property and equipment, net	102	353
Operating lease, right-of-use ("ROU") asset	9,099	6,731
Restricted cash	568	568
Total assets	$219,588	$140,403
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$1,585	$2,249
Accrued expenses	11,383	6,287
Operating lease obligations, current portion	1,000	338
Total current liabilities	13,968	8,874
Operating lease obligations, net of current portion	8,829	6,296
Total liabilities	22,797	15,170
Commitments and Contingencies (Note 12)
Stockholders' equity:
Common stock, $0.0001 par value: 300,000 shares authorized; 178,324 shares issued and outstanding at December 31, 2025; 137,820 shares issued and outstanding at December 31, 2024	18	14
Additional paid-in-capital	627,665	489,692
Accumulated other comprehensive income	280	210
Accumulated deficit	(431,172)	(364,683)
Total stockholders' equity	196,791	125,233
Total liabilities and stockholders' equity	$219,588	$140,403

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.